Reporter Seongmin Kim, Bio Spectator
Targeting 5 types of solid cancer including non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, rectal cancer, and pancreatic cancer…
NeoImmuneTech’s clinical development’NT-I7 (efineptakin alfa)’ and Merck’s (MSD) PD-1 immune anticancer drug’Pembrolizumab’ were administered in combination. It was announced on the 23rd that the first patient administration in phase 2 had begun.
Phase 2 clinical trials target 150 patients with 5 types of relapsed or refractory advanced solid cancer, and Neoimmuntech will evaluate the safety and therapeutic efficacy of drugs in combination with NT-I7 and Kitruda through this clinical trial. Specific target carcinomas are non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple negative breast cancer (TNBC), rectal cancer (MSS-CRC), and pancreatic cancer (PC).
Among them, patients with triple negative breast cancer, non-small cell lung cancer, and small cell lung cancer target patients who have already been treated with an immune checkpoint inhibitor, and patients with rectal cancer and pancreatic cancer target patients who have not been treated with an immune checkpoint inhibitor. The company expects that through clinical trials for each patient group, more precise analysis and key results for the treatment regimen will be possible.
The results for clinical 1b will be presented at the upcoming American Society of Clinical Oncologist (ASCO).
Yang Se-hwan, CEO of Neoimmuntech, said, “By co-administration of Kitruda and NT-I7, we plan to demonstrate whether the activity is increased and whether the tumor targets resistant to immune checkpoint inhibitors have anticancer effects.” “Through this, various types of solid cancer patients We expect to be able to present new treatment alternatives to people.”